Mr. Eric So reports

CYBIN ANNOUNCES SENIOR LEADERSHIP CHANGES

Effective Sept. 2, 2025, Doug Drysdale will step down as Cybin Inc.'s chief executive officer.

The company's co-founder and president, Eric So, has been appointed as interim chief executive officer by the board of directors.

"Cybin was founded with a singular mission: to transform the treatment paradigm for mental health. With a solid foundation of clinical progress, regulatory recognition and strong partnerships, we remain well positioned to drive our programs forward," said Eric So, interim chief executive officer. "I am committed to ensuring continuity during this transition and to maintaining our focus on creating long-term value for both patients and shareholders."

Mr. So continued: "I want to thank Mr. Drysdale for his contributions. As interim CEO, I look forward to executing on our strategy, advancing our clinical pipeline to successful approval of CYB003 and CYB004, and working closely with our partners as we move toward delivering innovative new therapies for patients in need."

Mr. So is a co-founder and executive chairman of Cybin. He is a veteran owner, operator and investor in numerous companies over the past 20 years and has led corporate strategy, development and finance at all stages of the business life cycle from start-up to growth stage and multinational.

The board of directors has established a committee to conduct a search for a new chief executive officer. The committee and the board aim to move swiftly to bring on-board a new leader who will lead the company through commercialization and ensure that Cybin delivers on its commitment to revolutionizing mental health care by developing new and innovative next-generation treatment options for patients.

About Cybin Inc.

Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental health care by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.

With promising class-leading data, Cybin is working to change the mental health treatment landscape through the introduction of novel drugs that provide effective and durable results for patients. The company is currently developing CYB003, a proprietary deuterated psilocin analogue, in phase 3 studies for the adjunctive treatment of major depressive disorder that has received breakthrough therapy designation from the U.S. Food and Drug Administration, and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a phase 2 study for generalized anxiety disorder. The company also has a research pipeline of investigational 5-HT-receptor-focused compounds.

Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom and Ireland.

We seek Safe Harbor.